A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression
A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Inclusion Criteria:
Exclusion Criteria:
medicalinformation@smmttx.com1-833-256-0522
North Venice, Florida 34275, United States
Omura-shi, Nagasaki 856-8562, Japan
Bunkyō-Ku, Tokyo 113-8677, Japan
Koto-Ku, Tokyo 135-8550, Japan
Querétaro, Mexico City 76269, Mexico
Sevilla, Madrid 41014, Spain